The Indian Journal of Pediatrics

, Volume 81, Issue 4, pp 368–370

Propranolol Treatment of Complicated Hemangiomas

Original Article



To evaluate laboratory and radiological features of hemangiomas in childhood in addition to efficacy and safety of propranolol as a first-line treatment of complicated hemangiomas retrospectively.


The files of 60 patients who were diagnosed as capillary hemangioma were evaluated retrospectively. Fourteen children with complicated hemangiomas treated with propranolol were analysed, in terms of side effects, efficacy and duration of treatment.


These fourteen patients (23 %) were treated with propranolol because of ulcerated, infected and/or deep seated localisations. The duration of treatment with propranolol were between 3 and 12 mo (median: 6 mo). Bronchospasm was observed in one patient during treatment. Except for two patients, all of them responded to propranolol treatment with limited side effects.


The present results support that propranolol is safe and effective treatment choice for complicated infantile hemangiomas, because of minimal side effects and encouraging response rates (80 %). In addition, the authors suggest that routine cranial radiological imagings might not be necessary for hemangiomas without any neurological symptoms.


Propranolol Corticosteroids Hemangioma 


  1. 1.
    Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.PubMedCrossRefGoogle Scholar
  2. 2.
    Zimmermann AP, Wiegand S, Werner JA, Eivazi B. Propranolol therapy for infantile haemangiomas: Review of the literature. Int J Pediatr Otorhinolaryngol. 2010;74:338–42.Google Scholar
  3. 3.
    Starkey E, Shahidullah H. Propranolol for infantile haemangiomas: A review. Arch Dis Child. 2011;96:890–3.Google Scholar
  4. 4.
    Price CJ, Lattouf C, Baum B, McLeod M, Schachner LA, Duarte AM, et al. Propranolol vs corticosteroids for infantile hemangiomas: A multicenter retrospective analysis. Arch Dermatol. 2011;147:1371–6.Google Scholar
  5. 5.
    Schwartz RA, Sidor MI, Musumeci ML, Lin RL, Micali G. Infantile haemangiomas: A challenge in paediatric dermatology. J Eur Acad Dermatol Venereol. 2010;24:631–8.Google Scholar
  6. 6.
    Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, et al. Propranolol for severe infantile hemangiomas: Follow-up report. Pediatrics. 2009;124:e423–31.Google Scholar
  7. 7.
    Schiestl C, Neuhaus K, Zoller S, Subotic U, Forster-Kuebler I, Michels R, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr. 2011;170:493–501.PubMedCrossRefGoogle Scholar
  8. 8.
    Manunza F, Syed S, Laguda B, Linward J, Kennedy H, Gholam K, et al. Propranolol for complicated infantile haemangiomas: A case series of 30 infants. Br J Dermatol. 2010;162:466–8.Google Scholar
  9. 9.
    Bertrand J, McCuaig C, Dubois J, Hatami A, Ondrejchak S, Powell J. Propranolol versus prednisone in the treatment of infantile hemangiomas: A retrospective comparative study. Pediatr Dermatol. 2011;28:649–54.Google Scholar
  10. 10.
    Fraley DS, Bruns FJ, Segel DP, Adler S. Propranolol-related bronchospasm in patients without history of asthma. South Med J. 1980;73:238–40.PubMedCrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2013

Authors and Affiliations

  1. 1.Department of Pediatric Hematology and Oncology, The Ministry of HealthŞanlıurfa Children’s HospitalŞanlıurfaTurkey
  2. 2.ÇankayaTurkey

Personalised recommendations